大行评级丨美银:重新覆盖微创医疗 予其“买入”评级及目标价16.8港元

中金财经
Yesterday

  美银证券重新覆盖微创医疗,予“买入”评级,目标价16.8港元,因公司近期的流动性压力已消除,投资者关注点由流动性风险回归到基本面。公司引入国企背景的上海实业作为战略股东,将支持财务与业务发展。该行预期,通过成本控制与处置非核心资产,公司有望于2026年上半年实现盈利。另外,海外业务快速增长,亦可分散国内市场风险,并提供长远增长能见度。   该行预测2025至27年收入分别为11.09亿、12.41亿及14.07亿美元,相当于按年增长7.6%、11.9%与13.3%,动力来自海外业务加速扩张及新产品上市;同时料营运开支比率和融资成本会进一步降低。      【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述、观点判断保持中立,不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考,并请自行承担全部责任。邮箱:news_center@staff.hexun.com   

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10